Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600178 · ClinicalTrials.gov registry record · Phase 1
Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)
A Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD), sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06600178: Recruiting Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD), sponsored by University of Virginia.
NCT06600178 is a Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD) that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 150 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06600178, a Phase 1 study of Coronary Microvascular Disease and Coronary Microvascular Dysfunction (CMD), is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease. Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR. AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo Participants will: * Take study drug or placebo for 12 weeks * Stress Cardiac magnetic resonance imaging * 12 lead electrocardiograms * Complete questionnaires
Primary Outcome
Coronary flow reserve is calculated as the ratio of hyperemic myocardial blood flow to the resting myocardial blood flow using cardiovascular magnetic resonance myocardial perfusion imaging
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brezavvy 20Mg Oral Tablet
Study Locations (1)
Virginia
- UVA Health - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
What NCT06600178 shows while recruiting
NCT06600178 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (150% higher).
The record links to 3 conditions, with Coronary Microvascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06600178 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06600178 about?
NCT06600178 is a clinical study titled "Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)". The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodiu...
What is the current status of trial NCT06600178?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-06-27. Estimated completion is 2026-10.
What conditions does trial NCT06600178 study?
This clinical trial studies the following conditions: Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD), Angina Patients With Non-obstructive Coronary Artery Disease.
What interventions are being tested in trial NCT06600178?
The interventions under investigation include: Placebo (DRUG), Brezavvy 20Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06600178?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600178 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Microvascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06600178's enrollment target sits among peer trials
150 364th of 2000 higher than 1,620 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI